The National Institutes of Health has halted a clinical trial evaluating the effectiveness of COVID-19 convalescent plasma in emergency department patients with mild-to-moderate COVID-19 symptoms and at least one risk factor for severe COVID-19 after an independent board concluded from the data that the treatment was unlikely to help such patients.

Forty-seven U.S. hospital EDs were participating in the study, which found no significant difference in outcomes for participants who received COVID-19 convalescent plasma or a placebo.

Related News Articles

Headline
As the Congressional Telehealth Caucus considers updates to legislation that would permanently remove all geographic restrictions on Medicare telehealth…
Headline
The Biden Administration plans to end on May 11 the COVID-19 national and public health emergencies declared in 2020, according to a policy statement …
Headline
The Centers for Medicare & Medicaid Services Friday released additional guidance on changes to the Medicaid continuous enrollment requirement under…
Headline
Between Oct. 10, 2022, and Jan. 8, 2023, nursing home residents who were not up to date with the recommended COVID-19 vaccinations had a 30%-50% higher risk…
Headline
The AHA is offering a new set of social messages and assets for February to encourage the public to get vaccinated and boosted against COVID-19. The new…
Headline
A Food and Drug Administration advisory committee unanimously voted today to recommend harmonizing the composition of all COVID-19 vaccine primary series and…